Peptide Manufacturing

01Modality overview and development process

Therapeutic peptides are chains of amino acids — typically 2 to 50 residues — occupying the space between small molecules and biologics. They combine the target selectivity of a biologic with synthetic, chemistry-based manufacture, which keeps them outside the cell-culture supply chain entirely. The development pathway runs from sequence and modification design, through synthesis-route selection and analytical method development, to GMP scale-up.

Complexity is driven less by length alone than by the modification profile: lipidation (as in the GLP-1 class), N-/C-terminal capping, cyclisation, disulfide bridge formation, and incorporation of non-natural or D-amino acids each add synthetic and purification burden. A 10-mer research peptide and a lipidated 30-mer commercial GLP-1 analogue sit at opposite ends of the difficulty curve even though both are "peptides."

02Manufacturing workflow and key technologies

• Solid-phase peptide synthesis (SPPS) — the dominant clinical/commercial route. Fmoc chemistry is the modern standard (Boc persists in legacy and certain difficult sequences). The chain is built C→N on a resin through iterative deprotection/coupling cycles, then cleaved and globally deprotected.
• Liquid-phase peptide synthesis (LPPS) — favoured for short sequences and at very large scale where solvent economics and convergent fragment coupling beat resin-based costs.
• Hybrid SPPS/LPPS — fragment condensation strategies that combine solid-phase assembly of fragments with solution-phase coupling; increasingly the cost-down route for multi-tonne GLP-1 supply.
• Purification — preparative reverse-phase HPLC is the workhorse; the number and column diameter of a CDMO's prep-HPLC suites is a direct proxy for usable capacity.
• Final form — lyophilisation and sterile fill/finish for injectable presentations.

Green-chemistry pressure is now a live procurement criterion: DMF and DCM reduction, solvent recovery, and lower process mass intensity affect both cost and regulatory/ESG posture at commercial scale.

03Development vs. commercial manufacturing requirements

Research-grade material is made at milligram-to-gram scale with non-GMP synthesis and characterisation sufficient for discovery. Clinical material requires ICH Q7 GMP, formal impurity control, and a defined analytical control strategy. Commercial supply — especially in the GLP-1 class — pushes into kilogram-to-multi-tonne scale, where solvent recovery, continuous or hybrid processing, and chromatography throughput become the binding constraints, not the chemistry itself.

The practical implication for sourcing: a CDMO that excels at clinical-scale GMP peptides may have no realistic path to commercial multi-tonne supply. Validate the scale ceiling explicitly rather than assuming continuity.

04Critical supplier selection criteria

• Synthesis platform breadth — SPPS, LPPS, and hybrid fragment-coupling capability under one roof signals scale-down/scale-up flexibility.
• Purification capacity — number and diameter of preparative HPLC suites; this, not reactor volume, gates peptide throughput.
• High-potency handling — containment for cytotoxic or potent peptide conjugates (OEB banding).
• Regulatory track record — active DMFs, FDA/EMA inspection history, prior approvals in your target market.
• Capacity availability — given GLP-1 backlog, confirmed slot availability and reservation terms matter more than nameplate capacity.
• Green-chemistry / solvent recovery — commercial cost and ESG implications.

05Regulatory and quality considerations by region

Synthetic peptide APIs fall under ICH Q7 GMP. Impurity control is the regulatory centre of gravity: peptide-related impurities (deletion, insertion, and truncated sequences; epimers; aggregates) must be characterised and controlled alongside ICH Q3C residual solvents and ICH Q3D elemental impurities. The FDA's guidance on synthetic peptide ANDAs referencing rDNA-origin reference products opened a defined generic pathway — directly relevant to generic GLP-1 programmes — and raises the bar on comparative impurity and immunogenicity-risk assessment. EMA expectations align broadly but verify regional specifics for your filing market.

06Common manufacturing challenges and how to mitigate them

• "Difficult sequences" / on-resin aggregation — mitigate with pseudoproline dipeptides, backbone-protecting groups, and elevated-temperature coupling.
• Epimerisation and deletion/insertion impurities — optimised coupling reagents (e.g. uronium/phosphonium activators), controlled coupling kinetics, and in-process monitoring.
• Low coupling efficiency on long chains — double-coupling, capping steps, and route redesign toward fragment condensation.
• Purity-vs-yield trade-off at scale — orthogonal purification (ion-exchange + reverse-phase) and modelled gradient scale-up.
• Chromatography scale-up risk — confirm the CDMO has scaled the specific separation, not just "has prep HPLC."

07Global supplier landscape and manufacturing hubs

Peptide capacity concentrates in North America, Western Europe (notably Switzerland, Germany, and Italy), and a fast-growing API base in India and China. The CDMO Hub directory lists 74 CDMOs referencing peptide capability across these regions.

08Capacity trends and market outlook

The GLP-1 wave (semaglutide, tirzepatide and follow-on analogues) has absorbed an unprecedented share of global peptide capacity, extending lead times and triggering multi-tonne capacity build-outs across the major API houses. Two second-order effects matter for sourcing teams outside the GLP-1 space: (1) capacity displacement — non-GLP-1 clinical programmes can be deprioritised behind blockbuster commercial demand; and (2) input-chain tightness in protected amino acids and resins. Research-grade and diagnostic peptide supply runs on a separate, less constrained dynamic, where supplier differentiation is about turnaround, catalogue breadth, and modification capability rather than tonnage.

09Typical development and scale-up timelines

10Questions to ask when evaluating potential CDMOs

• What is your realistic scale ceiling for this sequence — and have you run this specific separation at that scale?
• How many preparative HPLC suites are dedicated vs shared, and what is current slot availability?
• Do you hold an active DMF, and what is your FDA/EMA inspection history for peptide products?
• What is your impurity-control strategy for deletion/insertion and epimer species at our purity spec?
• What solvent-recovery and green-chemistry measures apply at commercial scale, and how do they affect cost?

11Recommended outsourcing strategy by development stage